Difference between revisions of "Zanubrutinib (Brukinsa)"
Jump to navigation
Jump to search
m |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Mantle cell lymphoma]] | *[[Mantle cell lymphoma]] | ||
| + | *[[Marginal zone lymphoma]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
| Line 15: | Line 16: | ||
*11/14/2019: Granted accelerated approval for adult patients with [[mantle cell lymphoma|mantle cell lymphoma (MCL)]] who have received at least one prior therapy. ''(Based on BGB-3111-206)'' | *11/14/2019: Granted accelerated approval for adult patients with [[mantle cell lymphoma|mantle cell lymphoma (MCL)]] who have received at least one prior therapy. ''(Based on BGB-3111-206)'' | ||
*8/31/2021: Approved for adult patients with [[Waldenström macroglobulinemia|Waldenström’s macroglobulinemia (WM)]]. ''(Based on ASPEN)'' | *8/31/2021: Approved for adult patients with [[Waldenström macroglobulinemia|Waldenström’s macroglobulinemia (WM)]]. ''(Based on ASPEN)'' | ||
| + | *9/14/2021: Accelerated approval for adult patients with relapsed or refractory [[Marginal zone lymphoma|marginal zone lymphoma (MZL)]] who have received at least one anti-CD20-based regimen. ''(Based on BGB-3111-214 and BGB-3111-AU-003)'' | ||
==Also known as== | ==Also known as== | ||
| Line 25: | Line 27: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
| + | [[Category:Marginal zone lymphoma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
Revision as of 02:08, 16 September 2021
General information
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 11/14/2019: Granted accelerated approval for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. (Based on BGB-3111-206)
- 8/31/2021: Approved for adult patients with Waldenström’s macroglobulinemia (WM). (Based on ASPEN)
- 9/14/2021: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. (Based on BGB-3111-214 and BGB-3111-AU-003)
Also known as
- Code name: BGB-3111
- Brand name: Brukinsa